NICE publish appraisal for venetoclax (Venclyxto▼) in treating chronic lymphocytic leukaemia
Venclyxto▼, for Chronic lymphocytic leukaemia from AbbVie
Wednesday 1st May 2019 | Source NICE | Type NICE decision
The National Institute for Health and Care Excellence (NICE) have recommended that AbbVie's chronic lymphocytic leukaemia treatment venetoclax, brand name Venclyxto▼, in combination with another medicine rituximab, as an option for treating chronic lymphocytic leukaemia.
The combination treatment is approved in adults who have had at least 1 previous therapy.
You can follow developments with this medicine using our Medicines Tracker service which provides users with updates about the medicines they are interested in, including updates to Patient Leaflets, information from medicine regulators and clinical trial information. To track information about this medicine please click on this article and follow the 'About this medicine' link then select 'Follow medicine'.
Why the committee made these recommendations
People with previously treated chronic lymphocytic leukaemia usually have ibrutinib. Clinical trial evidence shows that venetoclax plus rituximab increases how long people live for before their disease gets worse compared with bendamustine plus rituximab (a combination that is not frequently used). There is no trial directly comparing venetoclax plus rituximab with ibrutinib. Indirect comparisons of venetoclax plus rituximab with ibrutinib have limitations, but can be used for decision making because there is no other evidence.
Estimates from the cost-effectiveness analyses range from venetoclax plus rituximab being less costly and more effective to it being less costly and less effective, when compared with ibrutinib. Although it is uncertain how effective venetoclax is compared with ibrutinib, a cost-comparison analysis shows that venetoclax plus rituximab is considered to be a cost-effective use of NHS resources and it is recommended for routine use in the NHS.
About Venclyxto (source EMA)
Venclyxto is a cancer medicine used to treat adults with a blood cancer known as chronic lymphocytic leukaemia (CLL).
Venclyxto can be used in combination with rituximab (another cancer medicine) in patients who have received at least one previous treatment.
It can also be used on its own in:
patients with particular genetic changes (17p deletion or TP53 mutation) that make them unsuitable for chemo-immunotherapy (a type of cancer treatment). In these patients, Venclyxto is used when medicines known as B‑cell receptor pathway inhibitors (ibrutinib and idelalisib) are not suitable or have failed.
patients who do not have these genetic changes after treatments with chemo-immunotherapy and a B‑cell receptor pathway inhibitor have both failed.
The active substance in Venclyxto, venetoclax, attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows the progression of the disease.
Venclyxto was first made available in the EU in 2016. It is manufactured by AbbVie.
European Medicines Agency website page for Venclyxto
New medicines and vaccines that are under additional monitoring have an inverted black triangle symbol (▼) displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means – it does not mean the medicine is unsafe. You should report all suspected adverse drug reactions (ADRs) for these products. ADRs can be reported by your doctor, pharmacist or online via the Yellow Card system.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.
Users of the Keep Me Informed web site (the "Site") are subject to the following terms and disclaimers ("Terms"). By continuing to use this web site you accept these Terms.
Keep Me Informed Limited ("KMI") reserves the right, in its sole discretion, to change these Terms from time to time. Any changes made will be effective from the date when the revised Terms appear on the Site.
Accessing our site
We make every effort to ensure the Site is available at all times but cannot guarantee uninterrupted access. KMI accepts no responsibility for any damages which may arise due to the web site being unavailable.
Access to the Site is permitted on a temporary basis. We may suspend, withdraw, discontinue or change all or any part of the Site without notice.
You may use the Site only for lawful purposes. You may not use the Site:
in any way that breaches any applicable local, national or international law or regulation;
in any way that is unlawful or fraudulent, or has any unlawful or fraudulent purpose or effect; or
to transmit, or procure the sending of, any unsolicited or unauthorised advertising or promotional material or any other form of similar solicitation (spam)
You also agree:
not to reproduce, duplicate, copy or re-sell any part of our site (except as otherwise provided for in these Terms); and
not to access without authority, interfere with, damage or disrupt:
any part of the Site;
any equipment or network on which the Site is stored;
any software used in the provision of the Site; or
any equipment or network or software owned or used by any third party.
You must treat as confidential your user login, password or any other piece of information included as part of our security procedures. You must not disclose it to any third party.
We have the right to disable any user login or password, whether chosen by you or allocated by us, at any time, if in our reasonable opinion, you have failed to comply with any of the provisions of these Terms.
If you know or suspect that anyone other than you knows your user login or password, you must promptly notify us at enquiries@keepmeinformed org.uk
Links are provided for information and convenience only. KMI cannot accept responsibility for the content or policies of any third party sites linked to from the Site. Third party sites are not under the control of KMI and you hereby acknowledge that KMI does not make any representation or warranty regarding the accuracy, timeliness, suitability, copyright compliance, legality, decency, or any other aspect of the content of such other sites. Inclusion of any such link on the Site does not imply endorsement of the third party site, nor does it imply any association with its operators. Likewise, not linking to a particular site does not imply a lack of endorsement.
Linking to our Site
If you wish to create a link to the Site the following conditions apply:
You must not establish a link in such a way as to suggest any form of association, approval or endorsement on our part where none exists without our written consent;
Links should not be used in a defamatory context;
You understand that specific page URLs are subject to change without notice; and
We reserve the right to withdraw linking permission without notice.
We do not guarantee the Site will be free from bugs or viruses.
You are responsible for configuring your information technology, computer programmes and platform in order to access our site. You should use your own virus protection software.
Misuse and Unauthorised Access
You must not misuse the Site by knowingly introducing viruses, trojans, worms, logic bombs or other material which is malicious or technologically harmful.
You must not attempt to gain unauthorised access to the Site, the server on which the Site is stored, or any server, computer or database connected to the Site.
You must not attack the Site via a denial-of-service attack or a distributed denial-of service attack. By breaching this provision, you would commit a criminal offence under the Computer Misuse Act 1990. We will report any such breach to the relevant law enforcement authorities and we will co-operate with those authorities by disclosing your identity to them. In the event of such a breach, your right to use the Site will cease immediately.
Disclaimer of warranties
All content is provided "as is" and "as available" for your use. The content is provided without warranties of any kind, either expressed or implied, including, but not limited to, implied warranties, fitness for a particular purpose, title or non-infringement. KMI do not warrant that
the content is accurate, reliable or correct;
this site will be available at any particular time or location;
any defects or errors will be corrected; or
the content is free of viruses or other harmful components.
Your use of this site is solely at your risk. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.
Limitation of liability
Under no circumstances shall KMI and its respective affiliates be liable for any direct, indirect, punitive, incidental, special, or consequential damages that result from the use of, or inability to use, this site. This limitation applies whether the alleged liability is based on contract, tort, negligence, strict liability, or any other basis, even if KMI or its respective affiliates have been advised of the possibility of such damage. Because some jurisdictions do not allow the exclusion or limitation of incidental or consequential damages, KMI and its respective affiliates' liability in such jurisdictions shall be limited to the extent permitted by law.
By using this Site you agree to defend, indemnify, and hold harmless KMI, its respective affiliates, managing directors, principals, agents, employees, contractors, officers, and directors from all liabilities, claims, and expenses, including solicitor's fees, that arise from: (a) any content posted by you to the Site; or (b) any use or misuse of this Site by you. KMI reserves the right, at its own expense, to assume the exclusive defence and control of any matter otherwise subject to indemnification by you, in which event you will cooperate with KMI in asserting any available defences.
Suspension and termination
We will determine, in our discretion, whether there has been a breach of these Terms through your use of the Site. When a breach of this policy has occurred, we may take such action as we deem appropriate.
A material breach of the Terms under which you are permitted to use the Site may result in our taking all or any of the following actions, with or without notice:
immediate, temporary or permanent withdrawal of your right to use the Site;
immediate, temporary or permanent removal of any material uploaded by you to our site;
issue of a warning to you;
legal proceedings against you for reimbursement of all costs on an indemnity basis (including, but not limited to, reasonable administrative and legal costs) resulting from the breach; or
further legal action against you.
We do not provide medical advice. You must always seek professional medical advice. In an emergency, always telephone the emergency services.
The material published on this Site is subject to copyright protection unless otherwise indicated.
Except for the downloading, printing and exporting of data pertaining to your own organisation and data pertaining to your trading partner(s), or where expressly stated otherwise, or where the Site's functionality explicitly permits, you are not permitted to copy, broadcast, download, store (in any medium), transmit, adapt or change in any way the content of the KMI web pages for any purpose whatsoever without the prior written permission of KMI.
When we collect data
We may collect personal information from you when you do the following through our websites:
subscribe to one of our services;
register as a user on one or more of our websites;
contact us with a question or complaint.
apply for jobs with us;
register to receive news from us.
We also collect certain information automatically about visitors to the Site, as described in our Cookies Policy.
What information do we collect?
company or personal postal address;
phone number (land line, mobile and fax);
How do we use the information we collect?
When you give us any personal information we use this information to:
enable you to use any services that we provide through our Site;
enable you to become a registered user of one or more of our Sites;
process your transaction or subscription and correspond with you accordingly;
provide you, in accordance with your communications preferences, with information about our products and services, our latest news or special offers which may be of interest to you;
track activity on our websites for market research purposes so that we can improve the usefulness and content of the Site but, in carrying out such activity, we use the personal information in aggregate and on an anonymous basis;
stop you posting or sending offensive, inappropriate or objectionable content anywhere on our Site or where you otherwise engage in any disruptive behaviour on the Site. This may involve informing relevant third parties such as your employer, e-mail/Internet provider and law enforcement agencies about the content and your behaviour; and
for website administration (including enabling us to respond to any comments on the Site or feedback you may give us).
Who we share the information with
We will not share or sell your personal information to third parties unless we are required to do so by law. We may share your information with third parties to provide services which you request or for the purposes of fraud prevention.
We may provide information at an aggregated statistical level about our customers, traffic patterns and related site information to third parties, but this information will not identify individuals or individual companies.
Storage of data
We will not store your personal information for any longer than we need to, however we may be obliged by law to store your communications and personal information including activity logs. We may also need to show details of these to government or authorised officials upon request. Like many websites, we use log files to monitor the effectiveness of our online marketing programmes.
If you prefer not to receive information from us and would like to be removed from our mailing list, please email us at email@example.com.
What are cookies?
Cookies are small text files which a website may put on your computer or mobile device when you first visit a site or page. The cookie will help the website recognise your device the next time you visit. Web beacons or other similar files can also do the same thing. We use the term "cookies" in this policy to refer to all files that collect information in this way.
Certain cookies contain personal information - for example, if you click to "remember me" when logging in, a cookie will store your username. Most cookies won't collect information that identifies you, and will instead collect more general information such as how users arrive at and use our Site, or a user's general location.
What sort of cookies do we use?
Our cookies perform the following different functions:
Some cookies are essential for the operation of our Site. For example, some cookies allow us to identify subscribers and ensure they can access the subscription only pages. If a subscriber opts to disable these cookies, they may not be able to access all of the content that a subscription entitles them to.
Analytical and/or Performance Cookies
Some cookies analyse how our visitors use the Site and allow us to monitor the Site's performance. They allow us to recognise and count the number of visitors and to see how visitors move around our Site when they are using it. This can help us to improve the way our Site works and ensure that users are finding what they are looking for quickly and easily. For example, we might use performance cookies to keep track of which pages are most popular, which method of linking between pages is most effective, and to determine why some pages are receiving error messages. We might also use these cookies to highlight articles or Site services that we think will be of interest to you based on your usage of the Site.
We use functionality cookies to allow us to remember your preferences for your return visits to our Site. For example, cookies save you the trouble of typing in your username every time you access the Site. This also enables us to personalise our content for you, greet you by name and remember your preferences.
Can I block cookies?
You can choose to block cookies but they do help you to get the most out of a web site. Please remember that if you do choose to disable cookies, you may find that certain sections of our Site do not work properly.
Choice of law and forum
These Terms shall be governed by and construed in accordance with the laws of England and Wales. You agree to the exclusive jurisdiction of the courts of England and Wales.